Pyrimidine nucleotide biosynthesis pathway

The pyrimidine nucleotide biosynthesis pathway is a multi-step metabolic route by which cells synthesize the pyrimidine nucleotides required for DNA and RNA (including uridine, cytidine, and thymidine monophosphates) from basic precursors such as glutamine, aspartate, bicarbonate, and ATP. There are two major arms: the de novo pathway, starting from small molecules, and the salvage pathway, recycling nucleobases. Key enzymatic steps include formation of carbamoyl phosphate (by carbamoyl phosphate synthetase II), construction of the pyrimidine ring (aspartate transcarbamoylase, dihydroorotase), subsequent conversion to orotate, addition of ribose phosphate (orotate phosphoribosyltransferase), and conversion to uridine monophosphate (UMP decarboxylase), which is further phosphorylated to other nucleotides such as CTP and TTP[1][2][3][4][5]. This pathway is tightly regulated and essential for cell growth and proliferation. Aberrations lead to a range of diseases, including orotic aciduria, immunodeficiency states, and cancer. Enzymes in this pathway, most notably dihydroorotate dehydrogenase (DHODH), are established targets for drugs used in oncology (for example, 5-fluorouracil) and immunomodulation (such as leflunomide for rheumatoid arthritis and multiple sclerosis)[3][4][8]. Drugs targeting this pathway generally act by inhibiting key enzymes, leading to impaired DNA/RNA synthesis, especially in rapidly dividing cells. However, because the pathway itself is not a single protein or receptor but a sequence of enzymes and metabolic reactions, it is best considered a collection of metabolic targets, not a discrete molecular entity suitable for singular listing as a drug target. Important note: The "Pyrimidine nucleotide biosynthesis pathway" is a biochemical pathway, not a single molecule, protein, or receptor. Thus, it does not fit the standard definition of a druggable molecular target (such as "Epidermal growth factor receptor" or "Dihydroorotate dehydrogenase"). Instead, individual enzymes within the pathway serve as drug targets. Entry as given here is not a canonical molecular target and should be flagged as such.

Other names

De novo pyrimidine synthesis pathwayOrotate pathwayPyrimidine nucleotide biosynthetic process

Inhibition of nucleotide synthesis enzymes (e.g., dihydroorotate dehydrogenase, orotate phosphoribosyltransferase); Depletion of pyrimidine nucleotide pools; Disruption of DNA/RNA synthesis in rapidly dividing cells